Clinical Trial Update: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pertuzumab in combination with trastuzumab and a taxane as first-line therapy for HER2-positive advanced breast cancer has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Pertuzumab (pertuzumab)
• Taxane (paclitaxel or docetaxel)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2020-09-25